Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 5, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time.

Philip M Arlen1, Fernando Bianco, William L Dahut

  • 1Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA.

The Journal of Urology
|April 22, 2008
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Granular soil densification using expansive resins.

Scientific reports·2026
Same author

The evolution of therapy for chronic osteoarthritic knee pain: Feasibility, safety and clinical outcomes of transpedal access for genicular artery embolization.

European journal of radiology·2026
Same author

Risk of thrombosis with thrombocytopaenia syndrome (TTS) after vaccination with AZD1222: a European VAC4EU post-authorisation safety study.

Vaccine·2026
Same author

Optometrist attitudes towards delivering intravitreal injections in Aotearoa New Zealand.

Clinical & experimental optometry·2026
Same author

Microbiome education at under-resourced institutions: current status, barriers, and approaches to successful implementation.

Journal of microbiology & biology education·2026
Same author

Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression.

EClinicalMedicine·2026

Standardizing prostate specific antigen doubling time calculations is crucial for predicting prostate cancer outcomes. This approach aids in assessing treatment efficacy and guiding clinical trial progression for better patient prognosis.

Area of Science:

  • Oncology
  • Biochemistry
  • Clinical Trials

Background:

  • Prostate specific antigen (PSA) is a key biomarker in prostate cancer.
  • PSA doubling time (PSAdt) is a valuable prognostic indicator.
  • Standardized definitions for PSAdt are needed for consistent clinical application.

Purpose of the Study:

  • To establish consensus on the definition and calculation of PSA doubling time.
  • To develop guidelines for using PSAdt in prostate cancer research and clinical practice.
  • To promote a unified approach for outcome analysis and reporting.

Main Methods:

  • A National Cancer Institute conference convened experts in September 2006.
  • The Prostate Specific Antigen Working Group was formed to define parameters.

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Experiment Videos

Last Updated: Jul 5, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

  • Guidelines were developed for the calculation and application of PSAdt.

    • Main Results:

    • Criteria for calculating PSA doubling time were established.
    • Evidence supporting PSAdt as a predictive factor for biochemical recurrence was reviewed.
    • The utility of PSAdt as a stratification factor in clinical trials was defined.

    Conclusions:

    • Investigators should calculate PSA doubling time for patient stratification in clinical studies.
    • PSAdt serves as an important measure of therapeutic activity and patient prognosis.
    • Common standards for PSAdt are essential for advancing prostate cancer treatments towards definitive end points like survival.